M. Alexander Otto is a journalist who writes for Medscape, focusing on medical news and advancements in the field of oncology. With a particular interest in breast cancer research and treatment, Alexander covers topics such as new drug approvals, radiation therapy guidelines, and emerging technologies in cancer care.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
M. Alexander Otto specializes in healthcare and pharmaceutical topics, particularly focusing on the oncology field. His coverage heavily relies on data citations, indicating a preference for evidence-based information.
Given the technical nature of his articles and reliance on data citations, M. Alexander Otto would most likely respond well to pitches that provide scientific or medical experts who can offer in-depth insights into new treatments, clinical trial results, or emerging trends within the field of oncology and pharmaceuticals.
He does not appear to have a specific geographic focus but seems globally oriented when covering medical treatments and advancements in cancer care.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Experts debate whether women at high risk for BC should receive tamoxifen at standard 20 mg dose or can get similar preventive benefit, with fewer toxicities, from lower dose.
The agency says there's a problem with the latest trial of perioperative immunotherapy for NSCLC: There's no way to tell whether people need to continue treatment after surgery.
Circulating tumor DNA (ctDNA) can help predict the risk of relapse in certain cases of early, high-risk breast cancer, according to study presented at the American Society of Clinical Oncology annual meeting.
A new study finds that hormone receptor positivity does not offer a strong positive prognostic advantage for young women with BRCA-associated breast cancer.
Immunotherapy has largely replaced chemotherapy as the last resort in patients at the end of life, but it's not always the right move.
Can patients with rectal cancer who have a near-complete clinical response to total neoadjuvant therapy be watched and potentially spared a permanent ostomy?
In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, experts remain cautiously optimistic.
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or no PD-L1 expressors doesn't outweigh the risks.
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
Patients with this rare end-stage cancer complication achieved a median overall survival of nearly a year with proton craniospinal irradiation.
(833) 317-6278 
